39,400 Orion A-shares converted into B-shares
| Source: Orion Oyj
Recommended Reading
-
ORION CORPORATION PRESS RELEASE 6 OCTOBER 2026 at 9.00 EEST Orion Pharma announces agreement with Qilu Pharma Europe for pembrolizumab biosimilar for European market Orion Corporation...
Read More -
Orion Pharma announces first patient dosed in Phase 1/2 clinical trial of ODM-216, the company’s first biologic candidate to reach clinical testing.
Read More